Eleison Pharmaceuticals Competitors and Similar CompaniesClear all
Eleison Pharmaceuticals's competitors and similar companies include StemMed, Tvardi Therapeutics, Exelixis and Halozyme Therapeutics.
 Eleison Pharmaceuticals Eleison Pharmaceuticals is a company engaged in the discovery and commercialization of drug candidates for cancers. |  StemMed StemMed is a pharmaceutical development and testing company that provides pre-clinical drug testing services using a panel of patient-derived xenograft (PDX) models of breast and pancreatic cancers. |  Tvardi Therapeutics Tvardi Therapeutics is a biotechnology company developing medicines for the treatment of cancer, chronic inflammation, and fibrosis. |  Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. | ||
Founding Date | Founding Date 2008 | Founding Date 2009 | Founding Date 2017 | Founding Date 1994 | Founding Date 1998 |
Type | Type Private | Type Private | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Princeton, US HQ | Locations Houston, US HQ | Locations Houston, US HQ Houston, US | Locations Alameda, US HQ | Locations San Diego, US HQ |
Employees | Employees 12 | Employees 2 | Employees 19 | Employees 1,14712% decrease | Employees 373157% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 8.2 b | Valuation ($) 6.4 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $2.3b (FY, 2025) | Revenue (est.) $1.4b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $83.7m (FY, 2025) | Cost of goods $228.8m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $2.2b (FY, 2025) | Gross profit $1.2b (FY, 2025) |
Net income | Net income N/A | Net income N/A | Net income N/A | Net income $782.6m (FY, 2025) | Net income $316.9m (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 88m | Total funding raised N/A | Total funding raised $ 171.9m |
For sources of this data, please see the company profile
View Company Profiles
StemMed
HQ
Houston, US
Employees
2
StemMed is a pharmaceutical development and testing company that provides pre-clinical drug testing services using a panel of patient-derived xenograft (PDX) models of breast and pancreatic cancers.
View companyTvardi Therapeutics
HQ
Houston, US
Employees
19
Tvardi Therapeutics is a biotechnology company developing medicines for the treatment of cancer, chronic inflammation, and fibrosis.
View company
Exelixis
HQ
Alameda, US
Employees
1,147↓ 12% decrease
Exelixis is an oncology company that develops cancer treatments.
View companyHalozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View company